title: Liver: the gut is a key target of therapy in hepatic encephalopathy.
abstract: Little progress has been made in the pharmacological management of patients with hepatic encephalopathy, partly because it is difficult to perform clinical trials in this group of patients. A new clinical trial now suggests that polyethylene glycol is more effective than the current standard first-line therapy in these patients.
authors.affiliation: Liver Failure Group, Institute for Liver and Digestive Health, University College London, Royal Free Hospital, Rowland Hill Street, London NW3 2PF, UK.
authors.forename: Rohit
authors.initials: R
authors.lastname: Sawhney
authors.affiliation: Liver Failure Group, Institute for Liver and Digestive Health, University College London, Royal Free Hospital, Rowland Hill Street, London NW3 2PF, UK.
authors.forename: Rajiv
authors.initials: R
authors.lastname: Jalan
mesh_terms: D005765:Gastrointestinal Agents / Q000627:therapeutic use; D006501:Hepatic Encephalopathy / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D007422:Intestines / Q000187:drug effects / Q000503:physiopathology; D007792:Lactulose / Q000494:pharmacology / Q000627:therapeutic use; D011092:Polyethylene Glycols / Q000494:pharmacology / Q000627:therapeutic use*; D012294:Rifamycins / Q000494:pharmacology / Q000627:therapeutic use; D000078262:Rifaximin; D016896:Treatment Outcome
chemical_list: D005765:Gastrointestinal Agents; D012294:Rifamycins; D011092:Polyethylene Glycols; D007792:Lactulose; D000078262:Rifaximin